Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data ...

Eli Lilly (NYSE:LLY) and AC Immune have amended their collaboration focused on Tau aggregation inhibitor small molecules for ...

Dapagliflozin was first approved in 2014 and works by reducing the reabsorption of glucose and sodium in the kidneys. The ...

Cornell scientists have taken a major step toward developing a safe, reversible, long-acting and 100% effective nonhormonal ...

This clinical-stage biotech focused on hypertension therapies reported a notable insider sale, according to new SEC filings.

Sanofi’s TSLP and IL-13 inhibitor has aced a pair of mid-stage studies for respiratory diseases, but missed on a phase 2 ...

Investing.com -- AC Immune SA (NASDAQ:ACIU) shares jumped 13.9% Tuesday following the announcement of an amended license and collaboration agreement with Eli Lilly and Company for Tau aggregation ...

Alembic’s cumulative tally now stands at 235 ANDA approvals from the USFDA, including 217 final approvals and 18 tentative ...

Lunsekimig is one of a trio of clinical candidates that Sanofi is developing as successors to its big-selling IL-3 and IL-13 ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Alongside the approval of Ponlimsi, the FDA is reviewing a BLA for TEV-45779, a biosimilar candidate for Xolair, covering all currently approved indications.

AC Immune amended its collaboration agreement with Eli Lilly, extending development of potential treatments for Alzheimer's disease and other neurodegenerative diseases. The Swiss biopharmaceutical ...